Bristol-Myers Squibb says cancer drug combination fails late-stage trial

Bristol-Myers Squibb Co said on Monday a combination of two of its cancer drugs, being tested as a maintenance therapy, did not meet the main goal of extending the lives of lung cancer patients in a late-stage trial.